Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 267

1.

Evaluating a New International Risk-Prediction Tool in IgA Nephropathy.

Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, Katafuchi R, Er L, Espino-Hernandez G, Kim SJ, Reich HN, Feehally J, Cattran DC; International IgA Nephropathy Network.

JAMA Intern Med. 2019 Apr 13. doi: 10.1001/jamainternmed.2019.0600. [Epub ahead of print] Erratum in: JAMA Intern Med. 2019 Jul 1;179(7):1007.

PMID:
30980653
2.

IgA nephropathy: "State of the art": a report from the 15th International Symposium on IgA Nephropathy celebrating the 50th anniversary of its first description.

Trimarchi H, Barratt J, Monteiro RC, Feehally J.

Kidney Int. 2019 Apr;95(4):750-756. doi: 10.1016/j.kint.2019.01.007.

PMID:
30904065
3.

Global capacity for clinical research in nephrology: a survey by the International Society of Nephrology.

Okpechi IG, Alrukhaimi M, Ashuntantang GE, Bellorin-Font E, Benghanem Gharbi M, Braam B, Feehally J, Harris DC, Jha V, Jindal K, Johnson DW, Kalantar-Zadeh K, Kazancioglu R, Levin A, Lunney M, Olanrewaju TO, Perkovic V, Perl J, Rashid HU, Rondeau E, Salako BL, Samimi A, Sola L, Tchokhonelidze I, Wiebe N, Yang CW, Ye F, Zemchenkov A, Zhao MH, Bello AK.

Kidney Int Suppl (2011). 2018 Feb;8(2):82-89. doi: 10.1016/j.kisu.2017.10.012. Epub 2018 Jan 19. Review.

4.

Global coverage of health information systems for kidney disease: availability, challenges, and opportunities for development.

See EJ, Alrukhaimi M, Ashuntantang GE, Bello AK, Bellorin-Font E, Benghanem Gharbi M, Braam B, Feehally J, Harris DC, Jha V, Jindal K, Kalantar-Zadeh K, Kazancioglu R, Levin A, Lunney M, Okpechi IG, Olanrewaju TO, Osman MA, Perl J, Qarni B, Rashid HU, Rateb A, Rondeau E, Samimi A, Sikosana MLN, Sola L, Tchokhonelidze I, Wiebe N, Yang CW, Ye F, Zemchenkov A, Zhao MH, Johnson DW.

Kidney Int Suppl (2011). 2018 Feb;8(2):74-81. doi: 10.1016/j.kisu.2017.10.011. Epub 2018 Jan 19. Review.

5.

Global access of patients with kidney disease to health technologies and medications: findings from the Global Kidney Health Atlas project.

Htay H, Alrukhaimi M, Ashuntantang GE, Bello AK, Bellorin-Font E, Benghanem Gharbi M, Braam B, Feehally J, Harris DC, Jha V, Jindal K, Kalantar-Zadeh K, Kazancioglu R, Kerr PG, Levin A, Lunney M, Okpechi IG, Olah ME, Olanrewaju TO, Osman MA, Parpia Y, Perl J, Qarni B, Rashid HU, Rateb A, Rondeau E, Salako BL, Sola L, Tchokhonelidze I, Tonelli M, Wiebe N, Wirzba I, Yang CW, Ye F, Zemchenkov A, Zhao MH, Johnson DW.

Kidney Int Suppl (2011). 2018 Feb;8(2):64-73. doi: 10.1016/j.kisu.2017.10.010. Epub 2018 Jan 19. Review.

6.

Global nephrology workforce: gaps and opportunities toward a sustainable kidney care system.

Osman MA, Alrukhaimi M, Ashuntantang GE, Bellorin-Font E, Benghanem Gharbi M, Braam B, Courtney M, Feehally J, Harris DC, Jha V, Jindal K, Johnson DW, Kalantar-Zadeh K, Kazancioglu R, Klarenbach S, Levin A, Lunney M, Okpechi IG, Olanrewaju TO, Perl J, Rashid HU, Rondeau E, Salako BL, Samimi A, Sola L, Tchokhonelidze I, Wiebe N, Yang CW, Ye F, Zemchenkov A, Zhao MH, Bello AK.

Kidney Int Suppl (2011). 2018 Feb;8(2):52-63. doi: 10.1016/j.kisu.2017.10.009. Epub 2018 Jan 19. Review.

7.

Global overview of health systems oversight and financing for kidney care.

Bello AK, Alrukhaimi M, Ashuntantang GE, Bellorin-Font E, Benghanem Gharbi M, Braam B, Feehally J, Harris DC, Jha V, Jindal K, Johnson DW, Kalantar-Zadeh K, Kazancioglu R, Kerr PG, Lunney M, Olanrewaju TO, Osman MA, Perl J, Rashid HU, Rateb A, Rondeau E, Sakajiki AM, Samimi A, Sola L, Tchokhonelidze I, Wiebe N, Yang CW, Ye F, Zemchenkov A, Zhao MH, Levin A.

Kidney Int Suppl (2011). 2018 Feb;8(2):41-51. doi: 10.1016/j.kisu.2017.10.008. Epub 2018 Jan 19. Review.

8.

Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update.

Coppo R, D'Arrigo G, Tripepi G, Russo ML, Roberts ISD, Bellur S, Cattran D, Cook TH, Feehally J, Tesar V, Maixnerova D, Peruzzi L, Amore A, Lundberg S, Di Palma AM, Gesualdo L, Emma F, Rollino C, Praga M, Biancone L, Pani A, Feriozzi S, Polci R, Barratt J, Del Vecchio L, Locatelli F, Pierucci A, Caliskan Y, Perkowska-Ptasinska A, Durlik M, Moggia E, Ballarin JC, Wetzels JFM, Goumenos D, Papasotiriou M, Galesic K, Toric L, Papagianni A, Stangou M, Benozzi L, Cusinato S, Berg U, Topaloglu R, Maggio M, Ots-Rosenberg M, D'Amico M, Geddes C, Balafa O, Quaglia M, Cravero R, Lino Cirami C, Fellstrom B, Floege J, Egido J, Mallamaci F, Zoccali C.

Nephrol Dial Transplant. 2018 Nov 9. doi: 10.1093/ndt/gfy302. [Epub ahead of print]

PMID:
30418652
9.

Protocol and rationale for the first South Asian 5-year prospective longitudinal observational cohort study and biomarker evaluation investigating the clinical course and risk profile of IgA nephropathy: GRACE IgANI cohort.

Alexander S, John GT, Korula A, Vijayakumar TS, David VG, Mohapatra A, Valson AT, Jacob S, Koshy PM, Rajan G, John EE, Matthai SM, Jeyaseelan L, Ponnusamy B, Cook T, Pusey C, Daha MR, Feehally J, Barratt J, Varughese S.

Wellcome Open Res. 2018 Jul 26;3:91. doi: 10.12688/wellcomeopenres.14644.1. eCollection 2018.

10.

Locally Prepared Solutions for Treating AKI in Low-Resource Environments.

Cullis B, Feehally J.

Perit Dial Int. 2018 Jul-Aug;38(4):240-241. doi: 10.3747/pdi.2018.00029. No abstract available.

PMID:
29987063
11.

Long- and short-term outcomes in renal allografts with deceased donors: A large recipient and donor genome-wide association study.

Hernandez-Fuentes MP, Franklin C, Rebollo-Mesa I, Mollon J, Delaney F, Perucha E, Stapleton C, Borrows R, Byrne C, Cavalleri G, Clarke B, Clatworthy M, Feehally J, Fuggle S, Gagliano SA, Griffin S, Hammad A, Higgins R, Jardine A, Keogan M, Leach T, MacPhee I, Mark PB, Marsh J, Maxwell P, McKane W, McLean A, Newstead C, Augustine T, Phelan P, Powis S, Rowe P, Sheerin N, Solomon E, Stephens H, Thuraisingham R, Trembath R, Topham P, Vaughan R, Sacks SH, Conlon P, Opelz G, Soranzo N, Weale ME, Lord GM; United Kingdom and Ireland Renal Transplant Consortium (UKIRTC) and the Wellcome Trust Case Control Consortium (WTCCC)-3.

Am J Transplant. 2018 Jun;18(6):1370-1379. doi: 10.1111/ajt.14594. Epub 2018 Feb 1.

12.

The population-level costs of immunosuppression medications for the treatment of glomerulonephritis are increasing over time due to changing patterns of practice.

Barbour S, Lo C, Espino-Hernandez G, Sajjadi S, Feehally J, Klarenbach S, Gill J.

Nephrol Dial Transplant. 2018 Apr 1;33(4):626-634. doi: 10.1093/ndt/gfx185.

PMID:
29106654
13.

Global Kidney Health Atlas (GKHA): design and methods.

Bello AK, Johnson DW, Feehally J, Harris D, Jindal K, Lunney M, Okpechi IG, Salako BL, Wiebe N, Ye F, Tonelli M, Levin A.

Kidney Int Suppl (2011). 2017 Oct;7(2):145-153. doi: 10.1016/j.kisu.2017.08.001. Epub 2017 Sep 20. Review.

14.

Immunosuppression in IgA Nephropathy: Guideline Medicine Versus Personalized Medicine.

Feehally J.

Semin Nephrol. 2017 Sep;37(5):464-477. doi: 10.1016/j.semnephrol.2017.05.019. Review.

PMID:
28863793
15.

Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.

Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, Monaghan H, Zhao M, Barbour S, Reich H, Cattran D, Glassock R, Levin A, Wheeler D, Woodward M, Billot L, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Wang HY, Perkovic V; TESTING Study Group.

JAMA. 2017 Aug 1;318(5):432-442. doi: 10.1001/jama.2017.9362.

16.

β1,4-galactosyltransferase 1 is a novel receptor for IgA in human mesangial cells.

Molyneux K, Wimbury D, Pawluczyk I, Muto M, Bhachu J, Mertens PR, Feehally J, Barratt J.

Kidney Int. 2017 Dec;92(6):1458-1468. doi: 10.1016/j.kint.2017.05.002. Epub 2017 Jul 24.

PMID:
28750925
17.

Assessment of Global Kidney Health Care Status.

Bello AK, Levin A, Tonelli M, Okpechi IG, Feehally J, Harris D, Jindal K, Salako BL, Rateb A, Osman MA, Qarni B, Saad S, Lunney M, Wiebe N, Ye F, Johnson DW.

JAMA. 2017 May 9;317(18):1864-1881. doi: 10.1001/jama.2017.4046.

18.

An update on the treatment of IgA nephropathy.

Barbour S, Feehally J.

Curr Opin Nephrol Hypertens. 2017 Jul;26(4):319-326. doi: 10.1097/MNH.0000000000000336. Review.

PMID:
28399021
19.

Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.

Fellström BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, Sørensen SS, Tesar V, Del Vecchio L; NEFIGAN Trial Investigators.

Lancet. 2017 May 27;389(10084):2117-2127. doi: 10.1016/S0140-6736(17)30550-0. Epub 2017 Mar 28.

PMID:
28363480
20.

Peritoneal Dialysis to Treat Patients with Acute Kidney Injury-The Saving Young Lives Experience in West Africa: Proceedings of the Saving Young Lives Session at the First International Conference of Dialysis in West Africa, Dakar, Senegal, December 2015.

Abdou N, Antwi S, Koffi LA, Lalya F, Adabayeri VM, Nyah N, Palmer D, Brusselmans A, Cullis B, Feehally J, McCulloch M, Smoyer W, Finkelstein FO.

Perit Dial Int. 2017 Mar-Apr;37(2):155-158. doi: 10.3747/pdi.2016.00178. Review.

PMID:
28360366
21.

Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group.

Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, Liu ZH, Roberts IS, Yuzawa Y, Zhang H, Feehally J; IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants.

Kidney Int. 2017 May;91(5):1014-1021. doi: 10.1016/j.kint.2017.02.003. Epub 2017 Mar 22. Review.

22.

Ethical issues in dialysis therapy.

Jha V, Martin DE, Bargman JM, Davies S, Feehally J, Finkelstein F, Harris D, Misra M, Remuzzi G, Levin A; International Society of Nephrology Ethical Dialysis Task Force.

Lancet. 2017 May 6;389(10081):1851-1856. doi: 10.1016/S0140-6736(16)32408-4. Epub 2017 Feb 24.

PMID:
28238456
23.

Improving global health: measuring the success of capacity building outreach programs: a view from the International Society of Nephrology.

Feehally J, Brusselmans A, Finkelstein FO, Harden P, Harris D, Manuzi G, Naicker S, Tonelli M, Cameron H.

Kidney Int Suppl (2011). 2016 Dec;6(2):42-51. doi: 10.1016/j.kisu.2016.09.002. Epub 2016 Nov 21.

24.

Renal replacement therapy for refugees with end-stage kidney disease: an international survey of the nephrological community.

Van Biesen W, Vanholder R, Vanderhaegen B, Lameire N, Wanner C, Wiecek A, Sever MS, Feehally J, Kazancioglu R, Rondeau E, Levin A, Harris D.

Kidney Int Suppl (2011). 2016 Dec;6(2):35-41. doi: 10.1016/j.kisu.2016.09.001. Epub 2016 Nov 21.

25.

A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy.

Haas M, Verhave JC, Liu ZH, Alpers CE, Barratt J, Becker JU, Cattran D, Cook HT, Coppo R, Feehally J, Pani A, Perkowska-Ptasinska A, Roberts IS, Soares MF, Trimarchi H, Wang S, Yuzawa Y, Zhang H, Troyanov S, Katafuchi R.

J Am Soc Nephrol. 2017 Feb;28(2):691-701. doi: 10.1681/ASN.2016040433. Epub 2016 Sep 9. Erratum in: J Am Soc Nephrol. 2017 May;28(5):1665.

26.
27.

The ISN 0by25 Global Snapshot Study.

Feehally J.

Ann Nutr Metab. 2016;68 Suppl 2:29-31. doi: 10.1159/000446202. Epub 2016 Jun 16.

28.

Recognition and management of acute kidney injury in the International Society of Nephrology 0by25 Global Snapshot: a multinational cross-sectional study.

Mehta RL, Burdmann EA, Cerdá J, Feehally J, Finkelstein F, García-García G, Godin M, Jha V, Lameire NH, Levin NW, Lewington A, Lombardi R, Macedo E, Rocco M, Aronoff-Spencer E, Tonelli M, Zhang J, Remuzzi G.

Lancet. 2016 May 14;387(10032):2017-25. doi: 10.1016/S0140-6736(16)30240-9. Epub 2016 Apr 13. Erratum in: Lancet. 2016 May 14;387(10032):1998.

PMID:
27086173
29.

The International Society of Nephrology (ISN) and the American Nephrologists of Indian Origin (ANIO) Online Clinical Nephropathology Certificate (CNC) program.

Bijol V, Farag YMK, Shah S, Feehally J, Singh AK.

Kidney Int. 2016 May;89(5):966-968. doi: 10.1016/j.kint.2015.11.035. No abstract available.

PMID:
27083269
30.

Should Immunosuppressive Therapy Be Used in Slowly Progressive IgA Nephropathy?

Feehally J, Barratt J.

Am J Kidney Dis. 2016 Aug;68(2):184-186. doi: 10.1053/j.ajkd.2016.03.001. Epub 2016 Apr 2. No abstract available.

PMID:
27046351
31.

"Saving Young Lives" with acute kidney injury: the challenge of acute dialysis in low-resource settings.

Smoyer WE, Finkelstein FO, McCulloch MI, Carter M, Brusselmans A, Feehally J.

Kidney Int. 2016 Feb;89(2):254-6. doi: 10.1016/j.kint.2015.10.009. No abstract available.

PMID:
26806823
32.

The MEST score provides earlier risk prediction in lgA nephropathy.

Barbour SJ, Espino-Hernandez G, Reich HN, Coppo R, Roberts IS, Feehally J, Herzenberg AM, Cattran DC; Oxford Derivation, North American Validation and VALIGA Consortia; Oxford Derivation North American Validation and VALIGA Consortia.

Kidney Int. 2016 Jan;89(1):167-75. doi: 10.1038/ki.2015.322.

PMID:
26759049
33.

The mucosa-kidney axis in IgA nephropathy.

Floege J, Feehally J.

Nat Rev Nephrol. 2016 Mar;12(3):147-56. doi: 10.1038/nrneph.2015.208. Epub 2015 Dec 30. Review.

PMID:
26714580
34.

Saving Young Lives: provision of acute dialysis in low-resource settings.

Smoyer WE, Finkelstein FO, McCulloch M, Carter M, Brusselmans A, Feehally J.

Lancet. 2015 Nov 21;386(10008):2056. doi: 10.1016/S0140-6736(15)00971-X. Epub 2015 Nov 20. No abstract available.

PMID:
26700390
35.

Glomerulonephritis from a chronically infected implanted device.

Feehally J.

Lancet. 2015 Dec 5;386(10010):2364. doi: 10.1016/S0140-6736(15)00826-0. No abstract available.

PMID:
26681292
36.

Tonsillectomy in a European Cohort of 1,147 Patients with IgA Nephropathy.

Feehally J, Coppo R, Troyanov S, Bellur SS, Cattran D, Cook T, Roberts IS, Verhave JC, Camilla R, Vergano L, Egido J, Wiecek A, Karkoszka H, Tesar V, Maixnerova D, Ots-Rosenberg M, Quaglia M, Rollino C, Magistroni R, Cusinato S, Cravero R, Peruzzi L, Lundberg S, Gesualdo L, Cancarini G, Feriozzi S, Ferrario F; VALIGA study of ERA-EDTA Immunonephrology Working Group.

Nephron. 2016;132(1):15-24. doi: 10.1159/000441852. Epub 2015 Nov 20.

PMID:
26586175
37.

Executive summary and conclusions from the European Hydration Institute Expert Conference on human hydration, health, and performance.

Benton D, Braun H, Cobo JC, Edmonds C, Elmadfa I, El-Sharkawy A, Feehally J, Gellert R, Holdsworth J, Kapsokefalou M, Kenney WL, Leiper JB, Macdonald IA, Maffeis C, Maughan RJ, Shirreffs SM, Toth-Heyn P, Watson P.

Nutr Rev. 2015 Sep;73 Suppl 2:148-50. doi: 10.1093/nutrit/nuv056.

PMID:
26290300
38.

Effects of acute and chronic hypohydration on kidney health and function.

Feehally J, Khosravi M.

Nutr Rev. 2015 Sep;73 Suppl 2:110-9. doi: 10.1093/nutrit/nuv046. Review.

PMID:
26290296
39.

A review of the role of exercise and factors affecting its uptake for people with chronic kidney disease (CKD) not requiring renal replacement therapy.

MacKinnon HJ, Feehally J, Smith AC.

Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2015;36(1):37-46. Review.

PMID:
26076773
40.

Patient and Staff Perceptions of Intradialytic Exercise before and after Implementation: A Qualitative Study.

Young HM, Hudson N, Clarke AL, Dungey M, Feehally J, Burton JO, Smith AC.

PLoS One. 2015 Jun 12;10(6):e0128995. doi: 10.1371/journal.pone.0128995. eCollection 2015.

41.

The Genetics of IgA Nephropathy: An Overview from Western Countries.

Feehally J, Barratt J.

Kidney Dis (Basel). 2015 May;1(1):33-41. doi: 10.1159/000381738. Epub 2015 Apr 23. Review.

42.

Steroid-resistant nephrotic syndrome with mutations in NPHS2 (podocin): report from a three-generation family.

Jain V, Feehally J, Jones G, Robertson L, Nair D, Vasudevan P.

Clin Kidney J. 2014 Jun;7(3):303-5. doi: 10.1093/ckj/sfu028. Epub 2014 Apr 2.

43.

International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology.

Mehta RL, Cerdá J, Burdmann EA, Tonelli M, García-García G, Jha V, Susantitaphong P, Rocco M, Vanholder R, Sever MS, Cruz D, Jaber B, Lameire NH, Lombardi R, Lewington A, Feehally J, Finkelstein F, Levin N, Pannu N, Thomas B, Aronoff-Spencer E, Remuzzi G.

Lancet. 2015 Jun 27;385(9987):2616-43. doi: 10.1016/S0140-6736(15)60126-X. Epub 2015 Mar 13. Review. No abstract available.

PMID:
25777661
44.

Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study.

Tesar V, Troyanov S, Bellur S, Verhave JC, Cook HT, Feehally J, Roberts IS, Cattran D, Coppo R; VALIGA study of the ERA-EDTA Immunonephrology Working Group.

J Am Soc Nephrol. 2015 Sep;26(9):2248-58. doi: 10.1681/ASN.2014070697. Epub 2015 Feb 12.

45.

Progressive Resistance Exercise Training in CKD: A Feasibility Study.

Watson EL, Greening NJ, Viana JL, Aulakh J, Bodicoat DH, Barratt J, Feehally J, Smith AC.

Am J Kidney Dis. 2015 Aug;66(2):249-57. doi: 10.1053/j.ajkd.2014.10.019. Epub 2014 Dec 18.

PMID:
25533601
46.

Effective CKD care in European countries: challenges and opportunities for health policy.

Bello AK, Levin A, Manns BJ, Feehally J, Drueke T, Faruque L, Hemmelgarn BR, Kernahan C, Mann J, Klarenbach S, Remuzzi G, Tonelli M; Kidney Health for Life Initiative.

Am J Kidney Dis. 2015 Jan;65(1):15-25. doi: 10.1053/j.ajkd.2014.07.033. Epub 2014 Nov 5.

PMID:
25455091
47.

David N.S. Kerr (1927-2014).

Feehally J.

Nephron Clin Pract. 2014;128(1-2):201-2. doi: 10.1159/000365980. Epub 2014 Nov 4. No abstract available.

PMID:
25376595
48.

Evidence-based classification of glomerular pathology.

Cook T, Roberts IS, Feehally J, Barratt J.

Kidney Int. 2014 Nov;86(5):1059. doi: 10.1038/ki.2014.248. No abstract available.

49.

Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens.

Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, Fasel D, Lata S, Prakash S, Shapiro S, Fischman C, Snyder HJ, Appel G, Izzi C, Viola BF, Dallera N, Del Vecchio L, Barlassina C, Salvi E, Bertinetto FE, Amoroso A, Savoldi S, Rocchietti M, Amore A, Peruzzi L, Coppo R, Salvadori M, Ravani P, Magistroni R, Ghiggeri GM, Caridi G, Bodria M, Lugani F, Allegri L, Delsante M, Maiorana M, Magnano A, Frasca G, Boer E, Boscutti G, Ponticelli C, Mignani R, Marcantoni C, Di Landro D, Santoro D, Pani A, Polci R, Feriozzi S, Chicca S, Galliani M, Gigante M, Gesualdo L, Zamboli P, Battaglia GG, Garozzo M, Maixnerová D, Tesar V, Eitner F, Rauen T, Floege J, Kovacs T, Nagy J, Mucha K, Pączek L, Zaniew M, Mizerska-Wasiak M, Roszkowska-Blaim M, Pawlaczyk K, Gale D, Barratt J, Thibaudin L, Berthoux F, Canaud G, Boland A, Metzger M, Panzer U, Suzuki H, Goto S, Narita I, Caliskan Y, Xie J, Hou P, Chen N, Zhang H, Wyatt RJ, Novak J, Julian BA, Feehally J, Stengel B, Cusi D, Lifton RP, Gharavi AG.

Nat Genet. 2014 Nov;46(11):1187-96. doi: 10.1038/ng.3118. Epub 2014 Oct 12.

50.

Peritoneal dialysis, acute kidney injury, and the Saving Young Lives program.

Finkelstein FO, Smoyer WE, Carter M, Brusselmans A, Feehally J.

Perit Dial Int. 2014 Jul-Aug;34(5):478-80. doi: 10.3747/pdi.2014.00041. No abstract available.

Supplemental Content

Loading ...
Support Center